Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study.

Authors

Jan Šoupal
Lenka Petruželková
George Grunberger, Beaumont Health
Aneta Hásková
Milan Flekač
Martin Matoulek
Ondřej Mikeš
Tomáš Pelcl
Jan Škrha
Eva Horová
Jan Škrha
Christopher G Parkin
Štěpán Svačina
Martin Prázný

Document Type

Article

Publication Date

1-1-2020

Publication Title

Diabetes Care

Abstract

OBJECTIVE: This study assessed the clinical impact of four treatment strategies in adults with type 1 diabetes (T1D): real-time continuous glucose monitoring (rtCGM) with multiple daily insulin injections (rtCGM+MDI), rtCGM with continuous subcutaneous insulin infusion (rtCGM+CSII), self-monitoring of blood glucose with MDI (SMBG+MDI), and SMBG with CSII (SMBG+CSII).

RESEARCH DESIGN AND METHODS: This 3-year, nonrandomized, prospective, real-world, clinical trial followed 94 participants with T1D (rtCGM+MDI,

RESULTS: At 3 years, the rtCGM groups (rtCGM+MDI and rtCGM+CSII) had significantly lower A1C (7.0% [53 mmol/mol],

CONCLUSIONS: rtCGM was superior to SMBG in reducing A1C, hypoglycemia, and other end points in individuals with T1D regardless of their insulin delivery method. rtCGM+MDI can be considered an equivalent but lower-cost alternative to sensor-augmented insulin pump therapy and superior to treatment with SMBG+MDI or SMBG+CSII therapy.

Volume

43

Issue

1

First Page

37

Last Page

43

Recommended Citation

Šoupal J, Petruželková L, Grunberger G, Hásková A, Flekač M, Matoulek M, Mikeš O, Pelcl T, Škrha J Jr, Horová E, Škrha J, Parkin CG, Svačina Š, Prázný M. Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study. Diabetes Care. 2020 Jan;43(1):37-43. doi: 10.2337/dc19-0888. Epub 2019 Sep 17. PMID: 31530663.

DOI

10.2337/dc19-0888

ISSN

1935-5548

PubMed ID

31530663